In this interview CEO Adam Hill & non-exec Chair Alistair Macdonald of Oncimmune (ONC ) take Vox Markets through:
Chairman's 1st impressions since joining, & where he's like to take the group. Start
Order progression & pipeline. 02:15
Typical contract sizes & work completed. 05:10
Strategic importance of obtaining preferred supplier status with Biopharmas. 09:00
Where new business is being won. 11:40
How to scale the group. 14:10
Underlying profitability of ImmunoINSIGHTS. 17:35
Progress on earlyCDT test. 18:50
M&A. 21:25
Funding position. 23:35
Ultimate goals over next 2-4 years. 24:50
Future newsflow. 27:30
*VIDEO* Q&A with Oncimmune CEO, Dr Adam M Hill and Chairman Alistair Macdonald
Oct 5, 2022Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.